This document provides information about an upcoming 2-day international masterclass on targeted drug delivery taking place in Basel, Switzerland from February 11-12, 2016. It introduces the 3 course leaders, who are experts in their fields, and provides an overview of the course content which will focus on the latest strategies and technologies for drug targeting delivery including nanoparticles, antibody-drug conjugates, vaccines, and regulatory issues. Attendees will gain practical experience preparing gold nanoparticles and networking opportunities. The document encourages registration and provides contact information.

1. VISIT OUR WEBSITE:
WWW.FLEMINGEUROPE.COM
TR
AININGCE
RTIFIED BY
THETRAIN
ER
QUALITY
GUARANTEE
MEET THE MASTERCLASS LEADERS
Prof. GERRIT BORCHARD, PhD
University of Geneva
Professor of Biopharmaceutics
Swiss Academy of Pharmaceutical Sciences
President
Prof. Gerrit Borchard is a licensed pharmacist and
obtained his Ph.D. in pharmaceutical technology
from the University of Frankfurt. After holding
several academic posts, he joined Enzon Pharmaceuticals, Inc. as
Vice President Research. In 2005, he was appointed Full Professor of
Biopharmaceutical Sciences at the University of Geneva. He has (co-)
authored more than 120 papers and book chapters, and is named
as an inventor on seven patents. Prof. Borchard serves as an advisor
for the pharmaceutical and biotech industry, and is involved in due
diligence procedures for international consulting firms. He is currently
chairing the Non-Biological Complex working party at the European
Directorate for the Quality of Medicine (EDQM).
Dr. HELEN TOWNLEY, BSc PhD
Oxford University
University Lecturer and Senior Research Fellow
Xerion Healthcare, Director
Dr. Townley is a senior research scientist and
lecturer at Oxford University, based at the
University‘s Begbroke Science Park. Her research
group focuses on the use of nanoparticles for
therapy, imaging and targeted drug delivery in
a number of different cancer types, but with particular emphasis on
paediatric cancers. She is also a co-founder and director of the recently
founded Xerion Healthcare Ltd. – a University spin-out company set to
commercialize rare earth doped titania nanoparticles for augmented
radiotherapy.
Prof. KEWAL JAIN MD, FFPM
Jain Pharma Biotech
Chief Executive Officer, Professor
Professor K. K. Jain is a neurologist/neurosurgeon
by training with fellowship qualifications from
the Royal Colleges of Surgeons in Canada and
Australia. After his retirement from clinical practice,
he has been working in the biotechnology/
biopharmaceuticals industry for several years.
He received graduate training in both Europe and USA, has held
academic positions in several countries and is a Fellow of the Faculty
of Pharmaceutical Medicine of the Royal College of Physicians of UK.
Currently he is a consultant at Jain PharmaBiotech. Prof. Jain’s 457
publications include 26 books (5 as editor and 21 as author) and 50
special reports, which have covered important areas in biotechnology,
gene therapy and biopharmaceuticals. His important recent books
include Handbook of Nanomedicine (2nd ed Springer 2012) and
Textbook of Personalized Medicine (2nd ed Springer, 2015).
11 - 12 February 2016
Basel, Switzerland
What‘s New, What‘s Next?
International Masterclass
Targeted
Drug
Delivery
KEY BENEFITS
• Review the biology of drug targeting
• Learn about drug targeting strategies
• Follow new trends in nanopharmaceuticals
• Prepare your own gold nanoparticles
• Keep up to date with latest regulatory issues
• Switch to personalized medicine
• Pick up what‘s new in vaccine delivery
• Gain an overview of drug delivery devices
Media Partners:

2. COURSE OVERVIEW
This interactive 2-day masterclass will provide a detailed overview
of the newest strategies and achievements in drug delivery and
targeting, with particular attention paid to the use of nanoparticles,
macromolecules, nucleic acids and small molecule conjugates.
Recent cutting-edge discoveries in the quickly developing field of
nanodiagnostics will be covered, and in addition, case studies on the
development of targeted drugs will be thoroughly discussed. Join
this unique event and explore industry insights with the supervision
and guidance of our highly recognized and respected trainers. The
training will be focused on highly relevant content and will offer great
networking opportunities within the industry. Focusing on theory
and practical application, this educational program will provide
R&D scientists, engineers and development managers with the latest
knowledge on drug targeting and regulatory issues.
WHO SHOULD ATTEND
• R&D Scientists and Managers
• Drug Delivery specialists
• Biotechnology
• Biochemists
• Engineers
• Formulation Development
• Intellectual Property
• Biotechnologists
• Regulatory Affairs Personnel
• CRO vendors
KEY TAKEAWAYS
• Interactive way through stimulation of discussions and giving
the participants an opportunity to advance their ideas.
• Mix of learning methods including lecture style
presentations, discussions, practical sessions
• The participants will develop a systematic evaluation,
understanding, and refining of drug delivery processes
• Certificate of Completion issued by the Trainers
• 5H+ of Networking with other industry experts
• Hands-On case studies from the trainer‘s experience
IN-HOUSE TRAINING OPPORTUNITY
Cost effective in-house courses tailored specifically for and
customized to your organisation’s needs, can be arranged at
your preferred location and time. If you would like to discuss this
opportunity further please contact our In-house trainings division at:
marek.babusiak@flemingeurope.com
OUR PHARMA & BIOTECH COMPANIES PARTICIPATION IN 2012-2015
3P Biopharmaceuticals, Abbvie, Abdi Ibrahim, ALIMS, AM Labor, Anvisa, Arsanis Biosciences, Aryogenbiopharma Co., Ascendis, Antheln, Bayer
Pharma AG, Bio Technology General, Bio-Fiocruz, Biocad, Biocon, Biopharma, BioIntegrator, Biotie Therapies, Bioceros, Biosidus, Biosun,
Biotechpharma UAB, Bioton, Blausiegel, Blirt, Boehringer Ingelheim Pharma, Celonic, Cellca, Cobra Biologics, Cinnagen Co., CJSC R-Pharm,
CMC Biologics, Cytos, Eurofarma, Gedeon-Richter, GemaBiotech S.A., Hikma, IBC Generium LLC, Insight Biopharmaceuticals, Kymos Pharma
Services, LEK, LFB Biotechnologies, Lonza, Lupin Limited, Merck Serono, Medac, Medizone, Monojo, Mylan, NDA Regulatory Service,
Nordmark, Novo Nordisk, PharmActive, Pliva Croatia, PPD, Probiotech, Protagen Protein Services, PSI CRO, R-Pharm, Reliance Life Sciences,
Rentschler, Richter – Helm Biologics, Sanofi-Aventis, Sanovel, Saudi Food & Drug Authority, Scigen Biopharma, SOBI, Sobhan Oncology Co.,
Swissmedic, Teva-Ratiopharm
ENJOY THE CITY OF BASEL
Basel will surprise you, as the home to almost 40 museums and galleries, numerous buildings by famous architects, top-quality restaurants
and international events, Basel is an ideal destination for a business trip. Its central location, first-class transport connections and
infrastructure make it one of the most important exhibition and congress cities in Europe. Moreover, the city is a home base for numerous
pharma companies and research institutes. Discovering Basel is a treat for the senses, the city centre is a huge shopping paradise with the
colourful and exciting nightlife that has something to offer for everyone.
Booking line: tel: +421 257 272 290 | fax: +421 255 644 490
M: +254 715 003 269
email: killian.mabena@flemingeurope.com | www.flemingeurope.com

3. DAY 1 | 11 February 2016
8:30 Registration & Coffee
8:55 Welcome note from Fleming Europe
9:00 Meet & Greet Session
9:10 Session 1: The Biology of Drug Targeting
• Kinetics of body disposition following i.v. injection of
nanopharmaceuticals
• Marked for removal: opsonization, immune recognition
and phagocytosis, selective opsonization
• Aspects of tumor biology relevant for targeting
Prof. Gerrit Borchard
10:30 Morning Coffee & Networking
11:00 Session 2: Targeting Strategies
• Avoiding immune recognition and enhanced PK profile:
PEGylation et al.
• Passive targeting: enhanced permeation and retention
(EPR) effect
• Active targeting strategies using small molecules,
antibody formats, aptamers
Prof. Gerrit Borchard
12:30 Lunch
13:30 Session 3: Antibody-Drug Conjugates
• Magic bullet to therapeutic: a short history of ADC
development
• Payload classes and their mechanisms of action
• Strategies for site-specific antibody coupling
• Target antigens for ADC
• New ADC formats
• Pharmacokinetic and non-clinical safety aspects of ADC
Prof. Gerrit Borchard
15:30 Afternoon Coffee & Networking
16:00 Session 4: Delivery of vaccines
• Innovative methods for delivery of vaccines:
transdermal, transnasal, microneedles, needle-less
delivery, electroporation, and nanotechnology-based
delivery
• Role of nanobiotechnology in vaccinology
(nanovaccinology): focus on viral diseases
• Vaccine adjuvants
Prof. Kewal K. Jain MD
17:30 Review of Day 1
19:00 Networking dinner
DAY 2 | 12 February 2016
9:00 Opening remarks from the masterclass leaders
9:05 Session 5: Nanomedicine
• Nanodiagnostics: molecular diagnostics, nanoparticles
for imaging and integration of diagnostics with
therapeutics
• Nanotechnology-based drug delivery: nanoformulations
of conventional drugs, nanoparticles as drugs, delivery
across barriers in the human body
• Important areas for applications of nanomedicine
• Personalized medicine
Prof. Kewal K. Jain MD
10:30 Morning Coffee & Networking
11:00 Session 6: Nanopharmaceuticals
• Liposomes
• Polymer conjugates
• Nanoparticles
• Regulatory status
• „Nanosimilars“
• Silica nanoparticles for imaging drug delivery
• Practical session on nanoparticle synthesis
Prof. Gerrit Borchard
Dr. Helen Townley
12:30 Lunch
13:30 Session 7: Devices & Bio-instrumentation
• Overview: catheters, pumps, injectors, inhalers,
implanted reservoirs, etc.
• Devices for targeted drug delivery to the nervous system
• Drug-device combinations
• Role of nanobiotechnology in devices for drug delivery
Prof. Kewal K. Jain MD
15:30 Afternoon Coffee & Networking
16:00 Session 8: DISCUSSION SESSION
• Xerion case study - Doped titania nanoparticles for
augmented radiotherapy
• Panel discussion
• Q & A session
Dr. Helen Townley
Prof. Kewal K. Jain MD
Prof. Gerrit Borchard
17:30 Closing remarks from the masterclass leaders
I would like to thank everyone, who has helped with the research and organization of this event. Special thanks goes to our trainers for
their commitment and for their generous and invaluable support.
Marek Babusiak PhD. – training producer
marek.babusiak@flemingeurope.com
Booking line: tel: +421 257 272 290 | fax: +421 255 644 490
M: +254 715 003 269
email: killian.mabena@flemingeurope.com | www.flemingeurope.com

4. Targeted Drug Delivery
11 - 12 February 2016 | Basel, Switzerland
Terms and Conditions:
These terms and conditions represent an integral part of this contract between Event Production, s.r.o. and a client, which is specified
above, and who by signing this registration form fully and without any doubt or uncertainty accepts all following terms and conditions:
1. Payment terms. Event Production, s.r.o. (hereinafter as “EP”) requires the full payment of the invoiced amount within 7 work-
ing days from the issue date of the invoice. EP reserves the right to refuse entry to any client who does not pay the invoice in full and on
time. If the payment is not received on EP’s account on the seventh day from the date of the issue of the invoice, EP is entitled to charge the Client
an overdue interest of 5% p.a. for every day, for which the Cleint’s payment is overdue. The registration fee includes: conference documentation,
admission to all conference sessions, lunches and refreshments, admission to networking social breaks during the event. The registration fee does
not include: travel, hotel accommodation, transfers or insurance.
2. Hotel accommodation. Overnight accommodation is not included in the registration fee. A reduced rate may be available for EP’s clients
at the hotel hosting the event. The reservation form will be sent to the client after the venue has been confirmed, but no later than one month
before the event begins.
3. Cancellation by client. The client has the right to cancel his/her participation in the event. Cancellation must be received by EP in writing,
either by mail, email or fax. If the client cancels with more than one month’s advance notice before the start of the event, EP shall be entitled to
retain and charge 50% of the total invoiced amount. If the client cancels with one month’s (or less) advance notice, or fails to attend the event,
then the client shall not be entitled to any refund nor any discount. Client’s failure to attend the event does not cancel, decrease or in any matter
waives the client’s obligation to fully pay the fee invoiced to the client by EP.
4. Cancellation by EP. While every reasonable effort is made to adhere to the advertised program, circumstances out of the control of EP can
arise, which may cause changes in the program, including but not limited to changes in the content, date(s), location or venue, or special features
of the planned event. Such circumstances include but are not limited to acts of terrorism, war, extreme weather conditions, compliance with
government requests, orders and legal requirements, failure of third party suppliers to timely deliver, and failure to register the minimum targeted
amount of attendees for a given event. EP reserves the right to change the content, date(s), location or venue and/or special features of an event,
to merge the event with another event, or to postpone it or cancel it entirely as appropriate under the circumstances. Client agrees that EP shall
not be liable for any cost, damage or expense which may be incurred by client as a consequence of the event being changed, merged with
another event, postponed or cancelled and client agrees to hold EP harmless and to indemnify EP for any liability caused by any such changes,
mergers, postponements or cancellations to the Client.
5. Cancellation of the event. In case EP cancels the event, EP may offer the client a full credit up to the amount actually paid by the client
to EP. This credit shall be valid for up to one year from the issue date of the invoice to attend any of EP’s events. The client shall not be entitled
to this credit as a contractual right.
6. Clients identification information. By signing of this sales contract and these terms and conditions the client gives full right to EP to
share the client’s identification information such as, but not limited to, client’s name, address, email addresses, phone numbers and names of
representatives with third parties, which participated on the same event as the client.
7. Governing law. This contract shall be governed and construed in accordance with the laws of the Slovak Republic (not including its conflict
of laws provisions). Any disputes arising out of this contract shall be brought before the courts of the Slovak Republic situated in the city of
Bratislava in the Slovak Republic.
8. Other currencies. In case that client requests payment in other than EP’s official currency (EUR), EP reserves the right to apply 8% currency
risk surcharge to the actual exchange rate.
Mlynské Nivy 71, 821 05 Bratislava, Slovakia
IČO: 44 59 74 52, IČ DPH: SK2022754448
1
Sales Contract Conference Code: BATD152
Please complete this form and send it back to:
E-mail to: killian.mabena@flemingeurope.com
or FAX.: +421 255 644 490
Client Identification Details
(Please complete form IN CAPITAL LETTERS for each client)
Ms Mrs Mr Surname:
Name:
Job Title:
Email:
Ms Mrs Mr Surname:
Name:
Job Title:
Email:
Ms Mrs Mr Surname:
Name:
Job Title:
Email:
Company/organisation Details
Name:
VAT Number:
(VAT No. for EU members / Tax Number for non-EU members)
Contact person:
Email:
Address:
City:
Country:
Phone:
Payment Method
Please debit my
Visa Eurocard/Mastercard Diners club
Card Billing Address:
Street:
City:
Post/Zip Code
Card Holder´s Name:
Card Holder´s Signature:
Card Number:
Visa CVC Number or Eurocard/Mastercard CVV Number
(last 3 digits on the back of the card)
Valid from Expiry Date
I agree to Event Production s.r.o. debiting my card.
Authorization and Acceptance of
Sales contract Terms Conditions
I hereby declare I am authorised to sign this contract and terms
conditions in the name of the company/organisation:
Name:
Date:
Signature:
Booking is invalid without a signature
Agreed Price of the service
18 € administration charge will be applied
Payment is required within 7 working days
If you wish to pay in USD ($) or GBP (£) please contact us for more details.
In the name of Event Production s.r.o. I hereby declare Event Production s.r.o.
will adhere to this sales contract terms conditions
Eduard Vacula, Director
1 Delegate € 2096